Opipramol, 4-[3-(5H-Dibenz[b,f]azepin-5-yl)-1-piperazinethanol, C23H29N3O, M=363.49 g/mol
Trade Marks: Insidon®, Opipramol-neuraxpharm®
Insidon is the most important anxiolytic primarily used in Germany.
Application
Preferred used as tendency-lightening anxiolytic for the treatment of generalized anxiety disorder (GAD), whereby the effect occurs only after 1-2 weeks. At the beginning of the treatment the effect is rather sedating. Compared with other representatives of the tricyclic antidepressants the inhibition effect on the Serotonine and Dopamine receptors is only small. However, Opipramol has a high affinity to sigma receptors.
Contraindications
Do not use in case of alcohol intoxication, diseased enlargement of the prostata or glaucom.
Interactions
Do not use together with MAO Inhibitors
Adverse Effects
In particular at the beginning of the therapy reduced reactivity.
Analytics
The determination of Opipramol blood level can take place after extraction by means of HPLC/DAD. Therapeutic levels 0.1-0.5 µg/ml.
